About Nutcracker Therapeutics
Nutcracker Therapeutics is a company based in Emeryville (United States) founded in 2018 by Benjamin Eldridge and Igor Khandros. Nutcracker Therapeutics has raised $227.04 million across 2 funding rounds from investors including Arch Venture Partners. Nutcracker Therapeutics offers products and services including RNA Therapeutics Platform. Nutcracker Therapeutics operates in a competitive market with competitors including Twist Bioscience, Nuclera Nucleics, Ansa Biotechnologies, DNA Script and Sensible Biotechnologies, among others.
- Headquarter Emeryville, United States
- Founders Benjamin Eldridge, Igor Khandros
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
- Legal Name Nutcracker Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$227.04 M (USD)
in 2 rounds
-
Latest Funding Round
$167 M (USD), Series C
Mar 29, 2022
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Nutcracker Therapeutics
Nutcracker Therapeutics offers a comprehensive portfolio of products and services, including RNA Therapeutics Platform.
End-to-end platform for RNA design, delivery, and manufacturing of treatments.
People of Nutcracker Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Nutcracker Therapeutics
Nutcracker Therapeutics has successfully raised a total of $227.04M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $167 million completed in March 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Nutcracker Therapeutics
Nutcracker Therapeutics has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Arch Venture Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on life science companies
|
Locked | Locked | Locked |
Investor details for Nutcracker Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Nutcracker Therapeutics
Investment portfolio details for Nutcracker Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Nutcracker Therapeutics
Detailed financials for Nutcracker Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Nutcracker Therapeutics Comparisons
Peer comparison for Nutcracker Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Nutcracker Therapeutics
Nutcracker Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Twist Bioscience, Nuclera Nucleics, Ansa Biotechnologies, DNA Script and Sensible Biotechnologies, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Synthetic DNA is synthesized via a semiconductor-based platform.
|
|
| Locked | Locked | Locked |
Desktop bioprinter for genes and proteins production is developed.
|
|
| Locked | Locked | Locked |
DNA synthesis technology using enzymes is provided.
|
|
| Locked | Locked | Locked |
Benchtop DNA printers for nucleic acid synthesis are developed.
|
|
| Locked | Locked | Locked |
Developer of mRNA technology for therapeutics and vaccines
|
Detailed competitors of Nutcracker Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Nutcracker Therapeutics
Complete news archive for Nutcracker Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nutcracker Therapeutics
Nutcracker Therapeutics was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Nutcracker Therapeutics is headquartered in Emeryville, United States. It is registered at Emeryville, California, United States.
Igor Khandros is the current CEO of Nutcracker Therapeutics. They have also founded this company.
Nutcracker Therapeutics is a funded company, having raised a total of $227.04M across 2 funding rounds to date.
Nutcracker Therapeutics was founded in 2018 and is based in Emeryville, United States. Proprietary technology is utilized to produce patient-specific mRNA therapeutics on single-use biochips within the biotechnology sector. Operations involve software-controlled automation for process management, rapid production cycles, and a library of delivery vehicles tailored to specific indications. This platform supports targeted therapeutic development.
Nutcracker Therapeutics's top competitors include Nuclera Nucleics, Twist Bioscience and Ansa Biotechnologies.
Nutcracker Therapeutics offers RNA Therapeutics Platform.
Nutcracker Therapeutics has 1 investor. Key investors include Arch Venture Partners.